English EN
What is the FDA GRAS position for plant peptides in the US?
Beyond Biopharma | Plant Protein Peptide FAQ
Short answer: In the United States, plant protein hydrolysates and peptides are normally marketed as GRAS (Generally Recognized As Safe) ingredients rather than as approved food additives. Most common plant proteins have a long history of food use, so a hydrolysate made from them is usually supported either by a self-affirmed GRAS conclusion held by the supplier or by a GRAS Notice filed with the FDA that has received a no-questions letter. GRAS status belongs to a specific ingredient made by a specific process, so an importer should obtain the supporting documentation and confirm that it covers the exact product being purchased.
What GRAS means in practice
GRAS is a legal route to market under the Federal Food, Drug, and Cosmetic Act. An ingredient is GRAS when qualified experts generally recognize it as safe under the conditions of its intended use, resting on published scientific evidence or on a history of common use in food before 1958. A GRAS ingredient does not need pre-market approval as a food additive, which is why most protein ingredients in the US reach the market this way.
The two common ways a supplier supports GRAS
- Self-affirmed GRAS. The manufacturer assembles a safety dossier and convenes a qualified panel of experts who conclude that the ingredient is GRAS. The conclusion stays in the supplier file; it is not filed with the FDA. Buyers receive a summary or a letter, not a public document.
- GRAS Notice with an FDA no-questions letter. The supplier files a notice under the GRAS Notification Program, and the FDA responds that it has no questions about the GRAS conclusion at that time. The notice and the response are published, so the basis is openly visible.
Both routes are legitimate. The important difference for a buyer is transparency: an FDA no-questions letter is easy to verify independently, while a self-affirmed conclusion has to be reviewed from the supplier dossier.
Why the notice is tied to one manufacturing process
A GRAS conclusion is written around defined identity, purity and use-level conditions. Hydrolysis changes the molecular weight profile of the protein and can change how the ingredient behaves in the diet. A conclusion reached for a plant protein isolate does not automatically extend to a hydrolysate made from it, and a conclusion reached for one enzyme system, purification route and specification does not extend to another. When a supplier changes enzyme, degree of hydrolysis, carrier or drying method, the supporting basis should be re-checked against the product you are buying.
Documents an importer should review
| Document | Why it matters |
|---|---|
| GRAS notice or self-affirmed dossier summary | Shows the safety basis and the intended use conditions |
| Ingredient identity and specification sheet | Confirms the notice matches your grade, DH and purity |
| Manufacturing process description | Separates isolate, hydrolysate and blended products |
| Certificate of analysis for each lot | Bridges the dossier to the material you actually receive |
| Allergen and labelling statements | GRAS status and allergen duties are separate questions |
Points that are often confused
- GRAS is not the same as certified organic, non-GMO verified, halal or kosher. Those are separate programmes with their own review.
- A GRAS conclusion does not override allergen labelling duties. A soy or wheat hydrolysate still has to be declared for the allergen it comes from.
- GRAS status is not transferable between suppliers. Two companies can sell a similar pea peptide, each resting on its own basis.
Related reading
For more detail, see how soy, wheat and walnut peptides are labelled for allergens, which certifications matter for plant peptides and how to evaluate a plant peptide manufacturer.
